Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
BACKGROUND
Animal studies have suggested that thiazolidinediones (TZDs) have antirestenotic properties. However, human data are lacking. The goal of this single-center study was to assess the target vessel revascularization (TVR) rate following percutaneous coronary intervention (PCI) among diabetic patients according to TZD use.


METHODS
A total of 325 consecutive diabetic patients who underwent PCI between January 2000 and December 2001 were included in the analysis. Among them, 82 patients were on TZD and 243 patients were on other hypoglycemic regimens. All patients were treated with stents and platelet glycoprotein IIb/IIIa inhibitors at the time of intervention. TVR and death/myocardial infarction/TVR were assessed at 1 year.


RESULTS
TZD patients were more likely to be younger, male and have hyperlipidemia. TVR occurred in 36.6% of TZD patients compared with 23.9% of non-TZD patients (p=0.04). One-year death, myocardial infarction and TVR occurred in 41.1% of TZD patients compared with 30.8% of non-TZD patients (p=0.04).


CONCLUSIONS
In this retrospective analysis, TZD therapy did not decrease the need for repeat revascularization following PCI. Prospective randomized studies are warranted.
Cho
Leslie
L
Department of Cardiology, Loyola University Medical Center, Maywood, IL 60153, USA. lcho@lumc.edu
Lewis
Bruce E
BE
Steen
Lowell H
LH
Leya
Ferdinand S
FS
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002423:Cause of Death; D003326:Coronary Circulation / Q000187:drug effects*; D023921:Coronary Stenosis / Q000401:mortality / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000401:mortality / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality; D000077205:Pioglitazone; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D000077154:Rosiglitazone; D015607:Stents; D015996:Survival Rate; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000009:adverse effects
D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone